Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Julia S. Anixt is active.

Publication


Featured researches published by Julia S. Anixt.


Current Psychiatry Reports | 2011

Update on Environmental Risk Factors for Attention-Deficit/Hyperactivity Disorder

Tanya E. Froehlich; Julia S. Anixt; Irene M. Loe; Vilawan Chirdkiatgumchai; Lisa Kuan; Richard Gilman

Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurobehavioral disorder affecting 5% to 10% of children. Although considered to be a highly familial disorder, ADHD heritability estimates of 60% to 80% highlight the considerable role that environmental factors may still play in disorder susceptibility. Proposed ADHD environmental risk factors include prenatal substance exposures, heavy metal and chemical exposures, nutritional factors, and lifestyle/psychosocial factors. This paper reviews the literature published in 2010 investigating the association between environmental risk factors and ADHD or related symptomatology. Sources of risk factor exposure and the proposed mechanism by which each exposure is linked to ADHD-related neurobehavioral changes are also reported. Methodologic limitations of the current literature are discussed, and guidelines for future study are proposed. An improved understanding of the role that environmental factors play in ADHD etiology is critical to future ADHD prevention efforts.


Autism Research | 2016

Maternal metabolic risk factors for autism spectrum disorder—An analysis of electronic medical records and linked birth data

Natalia Connolly; Julia S. Anixt; Patty Manning; Daniel Ping-I Lin; Keith Marsolo; Katherine Bowers

Past studies have suggested that conditions experienced by women during pregnancy (e.g. obesity and gestational diabetes mellitus (GDM)) may be associated with having a child with autism spectrum disorder (ASD). Our objective was to compare mothers who had a child diagnosed with ASD to mothers of children with a non‐ASD developmental disorder (DD) or without any reported DD (controls). To accomplish the objective we collected medical record data from patients who resided in the Cincinnati Childrens Hospital Medical Centers (CCHMC) primary catchment area and linked those data to data from birth certificates (to identify risk factors). Two comparison groups were analyzed; one with DD; and the other, controls without a reported ASD or DD. Descriptive statistics and regression analyses evaluated differences. Differences were greater comparing mothers of ASD to controls than comparing ASD to DD. Maternal obesity and GDM were associated with a statistically significant approximately 1.5‐fold increased odds of having a child with an ASD. For mothers with both GDM and obesity, the association was twofold for having a child with ASD compared with controls. Maternal obesity and GDM might be associated with an increased risk of ASD in the offspring; however, no difference in risk of ASD according to BMI and GDM was seen when comparing to DD. Autism Res 2016, 9: 829–837,.


Congenital Heart Disease | 2016

Does Congenital Heart Disease Affect Neurodevelopmental Outcomes in Children with Down Syndrome

Tarek Alsaied; Bradley S. Marino; Anna J. Esbensen; Julia S. Anixt; Jeffery N. Epstein; James Cnota

OBJECTIVE The impact that congenital heart disease (CHD) has on the neurodevelopment of children with Down syndrome (DS) is unknown and potentially has implications for targeted early intervention. This study assessed the relationship between CHD that required surgery in the first year of life and neurodevelopmental, behavioral and emotional functioning outcomes in children with DS. METHODS A retrospective chart review of 1092 children (0-18 years) with DS who visited a single institution from 8/08-8/13 was performed. Children who underwent at least one of nine neurodevelopmental (cognitive, language, developmental) or academic tests were included in the analysis (N = 178). Cohort was age-divided into infants/toddlers (0-2 years), preschoolers (3-5 years), and school age/adolescent (6-18 years). Test scores of children with DS who underwent cardiac surgery in the first year of life were compared to children with DS without CHD. T test, chi-square and Mann Whitney U tests were used where appropriate. RESULTS Infants/toddlers with cardiac surgery had lower scores for receptive (P = .01), expressive (P = .021) and composite language (P < .001) compared to those with no CHD. Preschoolers with cardiac surgery had lower language scores and lower visual motor scores, although not statistically significant. In school age children with cardiac surgery there were no differences in IQ scores, language scores, or academic achievement scores compared to those without CHD. Also at school-age there was no difference in the incidence of ADHD, executive function or on internalizing and externalizing behavior scores. CONCLUSION Children with DS undergoing cardiac surgery during the first year demonstrated poorer neurodevelopmental outcomes as infants/toddler but had no difference at school age compared to children with DS without CHD. These results will guide early interventions to optimize neurodevelopmental outcomes in children with DS and will help with family counseling after CHD repair.


Journal of Consulting and Clinical Psychology | 2017

Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial.

Leanne Tamm; Carolyn A. Denton; Jeffery N. Epstein; Christopher Schatschneider; Heather B. Taylor; L. Eugene Arnold; Oscar G. Bukstein; Julia S. Anixt; Anson J. Koshy; Nicholas Newman; Jan Maltinsky; Patricia Brinson; Richard E. A. Loren; Mary R. Prasad; Linda Ewing-Cobbs; Aaron J. Vaughn

Objective: This trial compared attention-deficit/hyperactivity disorder (ADHD) treatment alone, intensive reading intervention alone, and their combination for children with ADHD and word reading difficulties and disabilities (RD). Method: Children (n = 216; predominantly African American males) in Grades 2–5 with ADHD and word reading/decoding deficits were randomized to ADHD treatment (medication + parent training), reading treatment (reading instruction), or combined ADHD + reading treatment. Outcomes were parent and teacher ADHD ratings and measures of word reading/decoding. Analyses utilized a mixed models covariate-adjusted gain score approach with posttest regressed onto pretest. Results: Inattention and hyperactivity/impulsivity outcomes were significantly better in the ADHD (parent Hedges’s g = .87/.75; teacher g = .67/.50) and combined (parent g = 1.06/.95; teacher g = .36/41) treatment groups than reading treatment alone; the ADHD and Combined groups did not differ significantly (parent g = .19/.20; teacher g = .31/.09). Word reading and decoding outcomes were significantly better in the reading (word reading g = .23; decoding g = .39) and combined (word reading g = .32; decoding g = .39) treatment groups than ADHD treatment alone; reading and combined groups did not differ (word reading g = .09; decoding g = .00). Significant group differences were maintained at the 3- to 5-month follow-up on all outcomes except word reading. Conclusions: Children with ADHD and RD benefit from specific treatment of each disorder. ADHD treatment is associated with more improvement in ADHD symptoms than RD treatment, and reading instruction is associated with better word reading and decoding outcomes than ADHD treatment. The additive value of combining treatments was not significant within disorder, but the combination allows treating both disorders simultaneously.


Journal of Developmental and Behavioral Pediatrics | 2015

Psychotropic Medication Use in Children and Adolescents With Down Syndrome.

Alison Downes; Julia S. Anixt; Anna J. Esbensen; Susan Wiley; Jareen Meinzen-Derr

Objective: To estimate the rate of psychotropic medication use in children and adolescents with Down syndrome (DS) and to describe age-related trends. Methods: Data were obtained from electronic health records from 2010 to 2013 for a retrospective cohort of 832 children with DS, aged 5 to 21 years, including 5324 visits. The following medication classes: central nervous system (CNS) stimulants, selective serotonin reuptake inhibitors, atypical antipsychotics, and alpha adrenergic agonists were examined. The distribution of rates of medication use across ages was assessed graphically and with the Cochran-Armitage trend test. Between-group comparisons of medication classes were conducted using &khgr;2. Repeated measures models with generalized estimating equations were used to assess changes in rates of medication use over time. Results: Children aged 12 to 21 years were more likely to be on any medication at some point compared with children aged 5 to 11 years (25% vs 17%, respectively, p = .003). For 5 to 11 year olds, the odds of being on a psychotropic medication increased with age for all medication classes studied. For 12 to 18 year olds, the odds of being on a CNS stimulant significantly decreased with increasing age (odds ratio: 0.73, 95% confidence intervals, 0.58–0.91), whereas the odds of being on a medication from one of the other classes was stable. Conclusion: Changes in psychotropic medication use across the age span in children with DS suggest that the type and severity of neurobehavioral problems in this population likely also change over time. These findings will inform future research on the common mental health conditions and treatments for children with DS.


Cardiology in The Young | 2017

High burden of genetic conditions diagnosed in a cardiac neurodevelopmental clinic.

Paula Goldenberg; Betsy J. Adler; Ashley Parrott; Julia S. Anixt; Karen Mason; Jannel Phillips; David S. Cooper; Stephanie M. Ware; Bradley S. Marino

BACKGROUND There is a known high prevalence of genetic and clinical syndrome diagnoses in the paediatric cardiac population. These disorders often have multisystem effects, which may have an important impact on neurodevelopmental outcomes. Taken together, these facts suggest that patients and families may benefit from consultation by genetic specialists in a cardiac neurodevelopmental clinic. OBJECTIVE This study assessed the burden of genetic disorders and utility of genetics evaluation in a cardiac neurodevelopmental clinic. METHODS A retrospective chart review was conducted of patients evaluated in a cardiac neurodevelopmental clinic from 6 December, 2011 to 16 April, 2013. All patients were seen by a cardiovascular geneticist with genetic counselling support. RESULTS A total of 214 patients were included in this study; 64 of these patients had a pre-existing genetic or syndromic diagnosis. Following genetics evaluation, an additional 19 were given a new clinical or laboratory-confirmed genetic diagnosis including environmental such as teratogenic exposures, malformation associations, chromosomal disorders, and single-gene disorders. Genetic testing was recommended for 112 patients; radiological imaging to screen for congenital anomalies for 17 patients; subspecialist medical referrals for 73 patients; and non-genetic clinical laboratory testing for 14 patients. Syndrome-specific guidelines were available and followed for 25 patients with known diagnosis. American Academy of Pediatrics Red Book asplenia guideline recommendations were given for five heterotaxy patients, and family-based cardiac screening was recommended for 23 families affected by left ventricular outflow tract obstruction. CONCLUSION Genetics involvement in a cardiac neurodevelopmental clinic is helpful in identifying new unifying diagnoses and providing syndrome-specific care, which may impact the patients overall health status and neurodevelopmental outcome.


Academic Pediatrics | 2018

Identifying Associations among Co-occurring Medical Conditions in Children with Autism Spectrum Disorders

Ann M. Neumeyer; Julia S. Anixt; James Chan; James M. Perrin; Donna S. Murray; Daniel L. Coury; Amanda E. Bennett; Justin Farmer; Robert A. Parker

OBJECTIVE Children with autism spectrum disorder (ASD) have a high prevalence of co-occurring medical conditions, including speech, sleep, and gastrointestinal disorders (constipation and feeding difficulties); developmental delay; attention deficit/hyperactivity disorder; hypotonia; epilepsy; anxiety; disruptive behavior; pica; and eczema. Less is known about whether these commonly coexist in the same children. We sought to determine clinically meaningful, statistically significant associations among co-occurring medical conditions in children with ASD that could lead to better understanding, identification, and treatment of these disorders. METHODS We studied 2114 children with ASD aged 17 months to 5years and 1221 children aged 6 to 17years at 15 Autism Speaks Autism Treatment Network Registry sites. Clinician-reported diagnoses and problems were grouped into 12 core conditions. We determined the observed prevalence (O) of co-occurring conditions and the estimated expected prevalence (E) across the network, adjusting for sitevariability in the prevalence of individual conditions. Pvalues were calculated using a Cochran-Mantel-Haenszel test stratified by site. We identified pairs of conditions co-occurring more frequently than expected (O/E >1) and less frequently than expected (O/E <1) and highlighted statisticallysignificant differences. RESULTS Among the 66 condition pairs for each age group, we confirmed previously identified associations, such as sleep disorders and anxiety symptoms, in older children. We found some associations not previously described, including feeding with sleep disorders (younger children only), constipation with sleep disorders, feeding with speech disorders, and constipation with speech disorders. CONCLUSIONS We have identified new associations among co-occurring medical conditions in children with ASD, offering the potential to examine common pathways.


Maternal and Child Health Journal | 2016

Shared Decision Making in the Care of Children with Developmental and Behavioral Disorders

Ellen A. Lipstein; Olivia J. Lindly; Julia S. Anixt; Maria T. Britto; Katharine E. Zuckerman


Journal of Developmental and Behavioral Pediatrics | 2018

Characteristics of Treatment Decisions to Address Challenging Behaviors in Children with Autism Spectrum Disorder

Julia S. Anixt; Jareen Meinzen-Derr; Halley Estridge; Laura Smith; William B. Brinkman


Current psychiatry | 2013

Expanding Medication Options for Pediatric ADHD: Psychostimulant and Non-Stimulant Agents Address the Symptoms of ADHD, Substantial Evidence Shows

Tanya E. Froehlich; Sergio V. Delgado; Julia S. Anixt

Collaboration


Dive into the Julia S. Anixt's collaboration.

Top Co-Authors

Avatar

Tanya E. Froehlich

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Anna J. Esbensen

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jareen Meinzen-Derr

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jeffery N. Epstein

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Sergio V. Delgado

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Aaron J. Vaughn

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Amanda E. Bennett

Children's Hospital of Philadelphia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anson J. Koshy

University of Texas Health Science Center at Houston

View shared research outputs
Researchain Logo
Decentralizing Knowledge